Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARFONAD vs DEL-VI-A
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Arfonad (trimethaphan camsylate) is a ganglionic blocking agent that competitively inhibits nicotinic acetylcholine receptors at autonomic ganglia, resulting in sympathetic and parasympathetic blockade. This leads to vasodilation and decreased peripheral vascular resistance.
Delvi-ā is a monoclonal antibody that binds to the interleukin-23 (IL-23) p19 subunit, inhibiting IL-23-mediated signaling and reducing inflammatory cytokine production.
Controlled hypotension during surgery,Hypertensive emergencies
Moderate to severe plaque psoriasis,Psoriatic arthritis,Crohn's disease
Intravenous infusion: 0.5-1 mg/min initially, titrated to desired blood pressure reduction; typical maintenance 1-4 mg/min.
10 mg orally once daily, taken with or without food.
Terminal elimination half-life is approximately 1-2 minutes due to rapid hydrolysis by plasma esterases, leading to ultrashort duration.
Terminal elimination half-life is 12-15 hours in patients with normal renal function. Half-life is prolonged to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and requires dose adjustment.
Primarily metabolized by plasma pseudocholinesterase (butyrylcholinesterase); also undergoes hepatic metabolism.
Metabolized via catabolic pathways into small peptides and amino acids.
Primarily renal excretion of unchanged drug (approximately 30-50%) with the remainder metabolized; minimal biliary/fecal elimination.
Renal excretion of unchanged drug accounts for 60-70% of elimination, with 20-30% excreted as glucuronide conjugate. Biliary/fecal excretion accounts for approximately 10%.
Approximately 50% bound to plasma proteins, primarily albumin.
Approximately 85% bound to serum albumin.
Approximately 0.3 L/kg, indicating distribution mainly in extracellular fluid.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water. Higher Vd in obesity (up to 1.2 L/kg) suggests extensive tissue binding.
Only administered intravenously; oral bioavailability is negligible due to rapid hydrolysis.
Oral bioavailability is 60-70% due to first-pass metabolism. No significant food effect observed.
No specific dose adjustment recommended based on GFR; use with caution in severe renal impairment due to potential for accumulation.
Cr Cl 30-89 m L/min: no adjustment; Cr Cl 15-29 m L/min: 5 mg once daily; Cr Cl <15 m L/min: not recommended.
No specific Child-Pugh based dose adjustments; caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Not recommended in pediatric patients due to lack of safety and efficacy data.
Not approved for patients <18 years. Safety and efficacy not established.
Initiate at lower end of dosing range (0.5 mg/min) and titrate slowly due to increased sensitivity to hypotension and reduced metabolic clearance.
No specific dose adjustment; use caution due to age-related renal impairment and potential for orthostatic hypotension.
None.
None.
May cause profound hypotension; monitor blood pressure closely.,Use with caution in patients with hypovolemia, myocardial ischemia, or cerebrovascular insufficiency.,Can cause histamine release leading to bronchospasm; avoid in patients with asthma.,May cause pupillary dilation and cycloplegia; use caution with glaucoma.,Can inhibit plasma pseudocholinesterase; prolonged effect in patients with atypical pseudocholinesterase.
Increased risk of infections including tuberculosis,Hypersensitivity reactions,Hepatic transaminase elevations
Hypersensitivity to trimethaphan or any component,Severe hypotension or shock,Myocardial infarction or coronary insufficiency,Uncompensated heart failure,Asthma or severe chronic obstructive pulmonary disease,Glaucoma (narrow-angle),Pregnancy (category C; may cause fetal harm)
Known hypersensitivity to delvi-ā or any excipients,Active serious infections
No specific food interactions; however, avoid large meals before surgery as general fasting guidelines apply.
Take with meals to reduce gastrointestinal side effects. Avoid high-fat meals as they may decrease delavirdine absorption. Grapefruit juice may increase delavirdine levels; avoid concurrent use. No other significant food interactions known.
Arfonad (trimethaphan camsylate) is a ganglionic blocker used for controlled hypotension. FDA Pregnancy Category C. Animal studies are inadequate. No well-controlled human studies. Potential for fetal harm due to maternal hypotension and reduced uteroplacental perfusion. First trimester: theoretical risk of teratogenicity due to altered hemodynamics, but no specific malformations reported. Second and third trimesters: risk of fetal hypoxia, bradycardia, and acidosis due to maternal hypotension. Avoid use in pregnancy unless clearly needed.
DEL-VI-A is contraindicated in all trimesters due to documented teratogenicity. First trimester exposure associated with neural tube defects and cardiovascular malformations. Second and third trimester exposure linked to fetal growth restriction and oligohydramnios.
No data on excretion in human milk. M/P ratio unknown. Caution: due to potential for ganglionic blockade in infant, consider benefit vs risk. A decision should be made to discontinue nursing or discontinue drug.
Excretion into breast milk is unknown; due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended. M/P ratio not available.
Pregnancy may alter pharmacokinetics; however, specific dose adjustments for Arfonad are not established. Use lowest effective dose. Rapid titration with continuous monitoring to achieve desired hypotensive effect while avoiding excessive hypotension and fetal compromise.
No safe dose established; drug is contraindicated in pregnancy. Due to altered pharmacokinetics (increased volume of distribution, enhanced clearance), if inadvertent exposure occurs, no dose adjustment can be recommended as any exposure poses fetal risk.
Arfonad (trimethaphan camsylate) is a ganglionic blocker used for controlled hypotension during surgery. Monitor blood pressure closely as it can cause profound hypotension. Tachyphylaxis develops rapidly. Use with caution in patients with renal impairment, as drug accumulation may occur. Administer via continuous IV infusion, titrating to desired effect. Have vasopressors (e.g., phenylephrine) ready to reverse hypotension. Arfonad can release histamine, so monitor for bronchospasm in asthmatics.
DEL-VI-A is a combination of delavirdine and vitamin A. Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1. Monitor for hepatotoxicity, especially in patients with hepatitis B/C coinfection or pre-existing liver disease. Administer with food to reduce GI upset. Vitamin A component may cause hypervitaminosis A if taken with other supplements. Use with caution in patients with renal impairment; no dose adjustment needed for mild-moderate, but avoid in severe (Cr Cl <30 m L/min).
You will receive this medication only in the hospital, typically during surgery.,Your blood pressure will be closely monitored throughout the infusion.,Report any difficulty breathing, hives, or palpitations immediately.,This medication may cause blurred vision, dizziness, or dry mouth; avoid sudden position changes.,Do not stop the infusion abruptly; it will be tapered by your healthcare team.
Take DEL-VI-A exactly as prescribed, typically three times daily with food.,Do not skip doses or stop taking without consulting your doctor, as this may lead to drug resistance.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, pale stools, or persistent nausea.,Avoid taking additional vitamin A supplements or multivitamins containing vitamin A to prevent toxicity.,DEL-VI-A does not cure HIV or prevent transmission; continue safe sex practices.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARFONAD vs DEL-VI-A, answered by our medical review team.
ARFONAD is a Ganglionic Blocker that works by Arfonad (trimethaphan camsylate) is a ganglionic blocking agent that competitively inhibits nicotinic acetylcholine receptors at autonomic ganglia, resulting in sympathetic and parasympathetic blockade. This leads to vasodilation and decreased peripheral vascular resistance.. DEL-VI-A is a Vitamin A supplement that works by Delvi-ā is a monoclonal antibody that binds to the interleukin-23 (IL-23) p19 subunit, inhibiting IL-23-mediated signaling and reducing inflammatory cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARFONAD and DEL-VI-A depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARFONAD is: Intravenous infusion: 0.5-1 mg/min initially, titrated to desired blood pressure reduction; typical maintenance 1-4 mg/min.. The standard adult dose of DEL-VI-A is: 10 mg orally once daily, taken with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARFONAD and DEL-VI-A in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARFONAD is classified as Category C. Arfonad (trimethaphan camsylate) is a ganglionic blocker used for controlled hypotension. FDA Pregnancy Category C. Animal studies are inadequate. No well-controlled human studies.. DEL-VI-A is classified as Category C. DEL-VI-A is contraindicated in all trimesters due to documented teratogenicity. First trimester exposure associated with neural tube defects and cardiovascular malformations. Secon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.